Neurizon Files IND Application to Support HEALEY ALS Platform Trial

Neurizon Therapeutics Limited Australia

[phone]

 

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease.  Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

Logo - https://mma.prnewswire.com/media/2530795/Neurizon_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/neurizon-files-ind-application-to-support-healey-als-platform-trial-302334461.html